Van ECK Associates Corp Has $20.28 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Van ECK Associates Corp lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 14.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,942,442 shares of the company's stock after selling 323,647 shares during the quarter. Van ECK Associates Corp owned about 0.17% of Teva Pharmaceutical Industries worth $20,279,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in TEVA. Blue Trust Inc. boosted its stake in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock valued at $46,000 after acquiring an additional 2,180 shares during the period. Signaturefd LLC increased its position in Teva Pharmaceutical Industries by 90.8% in the third quarter. Signaturefd LLC now owns 5,032 shares of the company's stock worth $51,000 after buying an additional 2,394 shares during the period. Desjardins Global Asset Management Inc. lifted its stake in Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company's stock valued at $85,000 after buying an additional 1,070 shares during the last quarter. Schechter Investment Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $117,000. Finally, DGS Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $119,000. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 31,766 shares of the business's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Mark Sabag sold 100,000 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now directly owns 382,590 shares of the company's stock, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 390,738 shares of company stock valued at $5,132,766. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded down $0.07 on Wednesday, reaching $13.98. 9,670,970 shares of the stock were exchanged, compared to its average volume of 10,515,718. The stock has a market cap of $15.67 billion, a PE ratio of -29.85, a PEG ratio of 1.69 and a beta of 1.05. The firm has a fifty day moving average price of $13.55 and a two-hundred day moving average price of $11.50. Teva Pharmaceutical Industries Limited has a twelve month low of $7.09 and a twelve month high of $14.47. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an "overweight" rating in a research note on Monday, February 5th. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Piper Sandler raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and upped their target price for the stock from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.